Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2003072736) REAGENTS AND TREATMENT METHODS FOR AUTOIMMUNE DISEASES
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2003/072736 International Application No.: PCT/US2003/005549
Publication Date: 04.09.2003 International Filing Date: 21.02.2003
Chapter 2 Demand Filed: 10.09.2003
IPC:
A61K 39/395 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
DUKE UNIVERSITY [US/US]; 230 North Building, Research Drive Box 90083 Durham, NC 27708-0083, US (AllExceptUS)
TEDDER, Thomas, F. [US/US]; US (UsOnly)
Inventors:
TEDDER, Thomas, F.; US
Agent:
MYERS, BIGEL, SIBLEY & SAJOVEC, P.A.; P.O. Box 37428 Raleigh, NC 27627, US
Priority Data:
60/359,41921.02.2002US
60/420,47221.10.2002US
Title (EN) REAGENTS AND TREATMENT METHODS FOR AUTOIMMUNE DISEASES
(FR) REACTIFS ET METHODES THERAPEUTIQUES DE MALADIES AUTO-IMMUNES
Abstract:
(EN) The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).
(FR) L'invention concerne des méthodes thérapeutiques utilisant des anticorps monoclonaux anti-CD22 faisant preuve de propriétés physiologiques uniques. L'invention concerne plus particulièrement des méthodes thérapeutiques de tumeurs malignes associées aux lymphocytes B et de maladies auto-immunes par administration d'une quantité efficace d'un anticorps monoclonal anti-CD22 de blocage spécifiquement lié aux deux premiers domaines de type Ig ou à un épitope se trouvant dans les deux premiers domaines de type Ig de CD22 humain natif (hCD22).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
KR1020040094705EP1485130JP2005526501CN1646161CA2476776AU2003224624